IRIDEX (NASDAQ:IRIX) Earns Hold Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of IRIDEX (NASDAQ:IRIX) in a research note issued to investors on Sunday morning. The brokerage issued a hold rating on the medical equipment provider’s stock.

IRIDEX Trading Down 1.2 %

Shares of IRIX opened at $1.61 on Friday. IRIDEX has a one year low of $1.27 and a one year high of $3.65. The stock has a 50-day moving average price of $1.70 and a 200 day moving average price of $1.81. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.85 and a current ratio of 1.54. The company has a market capitalization of $26.83 million, a P/E ratio of -2.41 and a beta of 0.82.

IRIDEX (NASDAQ:IRIX) last issued its quarterly earnings results on Tuesday, November 12th. The medical equipment provider reported ($0.12) EPS for the quarter. IRIDEX had a negative return on equity of 192.95% and a negative net margin of 22.79%. The company had revenue of $11.58 million for the quarter. During the same quarter last year, the firm earned ($0.11) earnings per share.

About IRIDEX

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments.